News zum Sektor Gesundheit aus Singapur

 

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

CytoMed Therapeutics Limited (the “Company”) (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies, today announced that on October 6, 2026, the Company received a notice from the staff of the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the last 30 consecutive business days, the closing bid price of the Company's ordinary shares (the “Ordinary Shares”) was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification letter has no current effect on the listing or trading of the Company's Ordinary Shares on Nasdaq....

Pharma - DKSH hat eine strategische Partnerschaft mit Novartis geschlossen, um den Zugang zu ophthalmologischen Lösungen in Singapur zu verbessern....

[The content of this article has been produced by our advertising partner.] As DBS Hong Kong and Manulife Hong Kong celebrate the 10th anniversary of their bancassurance partnership, the two organizations are marking the milestone with a HK$1 million donation to Oasis – Centre for Personal Growth & Crisis Intervention, a centre under the Hospital Authority's Corporate Clinical Psychology Services. The milestone also reflects a decade of collaboration in helping customers protect their wealth and......

Encare AB has signed an agreement with FV Hospital (Far East Medical Vietnam), its first partner hospital in Vietnam, to implement Enhanced Recovery After Surgery (ERAS[®]) across two surgical pathways: colorectal surgery and hip and knee arthroplasty. FV Hospital is a private hospital in Ho Chi Minh City and part of Thomson Medical Group, one of Southeast Asia's leading healthcare groups. [Encare_FV_Hospital_Vietnam_ERAS.png] FV Hospital in Ho Chi Minh City becomes Encare's first partner hospital in Vietnam. STOCKHOLM, Sweden and HO CHI MINH CITY, Vietnam, 7 October 2026 – As part of...

Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers...

Candidate selected by GSK utilizes Wave's best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing...

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases....

WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave's INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 alone ...

Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

CNBC's Jim Cramer took a fresh look at five stocks viewers asked about, including ExlService, MakeMyTrip, Establishment Labs, NVE and Ubiquiti....

Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), today announced the completion of the redomiciliation process to change the parent company of the Wave group of companies from a Singapore company to a Delaware corporation by way of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Redomiciliation”)....

UOB Kay Hian issued a research report stating that BEONE MEDICINES (06160.HK)'s revenue for the first half of the year rose 32.3% YoY to USD3.219 billion, while adjusted net profit increased 110.7% YoY to USD820 million, both exceeding the broker's and market expectations. Interim revenue and adjusted net profit accounted for 49......

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave's management team are scheduled to participate in two upcoming investor conferences in August....

Find insight on Bayer, Parkway Life, Fresenius Medical Care and more in the latest Market Talks covering health care....

WVE-007 obesity candidate shows 16.5% visceral fat improvement in early trials....